Alendronate sodium Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Alendronate sodium is the fourth bisphosphonate to reach the market for the treatment of postmenopausal osteoporosis. Bisphosphonates are potent inhibitors of bone resorption. They reduce pain and complications due to bone metastases, are effective in Paget's disease and in increasing bone mineral density. These agents bind tightly to hydroxyapatite crystals and are retained on bone resorption surfaces. Local release of the bisphosphonates occurs by acidification during the process of the bone resorption to impair the osteoclasts' ability to resorb bone. Alendronate is more potent than other bisphosphonates such as clodronate, pamidronate, and etidronate and is reported to have no deleterious effects on bone. It has also been shown to reduce hypercalcemia in cancer patients.

Pharmakokinetik

The second-generation agent alendronate sodium was the first bisphosphonate agent approved by the U.S. FDA for the prevention and treatment of osteoporosis and Paget's disease of the bone and is 1,000-fold more potent than etidronate. This derivative, when dosed continuously (5–10 mg/day for osteoporosis and 40 mg/day for Paget's disease) and given with oral calcium supplements (500 mg/day), produced well-mineralized bone and significantly improved BMD (7% in the spine and 4% in the hip) within 18 months. In addition, the vertebral fracture rate was shown to decrease by 47%. A side effect associated with alendronate, chemical esophagitis, has been attributed to inadequate intake of water and lying down after taking the medication. Specific patient instructions were developed to limit the incidence of upper gastrointestinal problems and include: 1) taking the medication with 6 to 8 ounces of water on arising in the morning, 2)remaining in an upright position for at least 30 minutes after taking the medication, and 3) delaying drinking other liquids/eating for at least 30 minutes, if not 1 to 2 hours, to allow maximal absorption of the agent. To enhance absorption, calcium supplements and any aluminum- or magnesium-containing antacids should be dosed separately from the agents in this class.

Clinical Use

The second-generation agent alendronate sodium was the first bisphosphonate agent approved by the U.S. FDA for the prevention and treatment of osteoporosis and Paget's disease of the bone and is 1,000-fold more potent than etidronate.

Alendronate sodium Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Alendronate sodium Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD	+8618291886785	olivia.wang@pushanshiye.com	China	164	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21634	55
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49374	58
career henan chemical co	+86-0371-86658258 +8613203830695	factory@coreychem.com	China	29811	58
Hebei Mojin Biotechnology Co., Ltd	+86 13288715578 +8613288715578	sales@hbmojin.com	China	12835	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
ANHUI WITOP BIOTECH CO., LTD	+8615255079626	eric@witopchemical.com	China	23541	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	22784	58
AFINE CHEMICALS LIMITED	+86-0571-85134551	sales@afinechem.com	China	15352	58
Baoji Guokang Bio-Technology Co., Ltd.	0917-3909592 13892490616	gksales1@gk-bio.com	China	9312	58

129318-43-0()Verwandte Suche:

---

• Alendronic acid, sodiuM salt
• sodium hydrogen (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate
• tetrasodium 4-amino-1,1-diphosphonato-butan-1-ol
• tetrasodium 4-amino-1,1-diphosphonatobutan-1-ol
• (4-Amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt
• 4-AMINO-1-HYDROXY-1-PHOSPHONOBUTYL PHOSPHONIC ACID, MONOSODIUM
• MK-217
• Alendronate sodium
• Sodium 4-amino-1-hydroxy-1-phosphonobutane-1-phosphonate
• Alendronate sodiumQ: What is Alendronate sodium Q: What is the CAS Number of Alendronate sodium Q: What is the storage condition of Alendronate sodium
• Phosphonic acid,P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1)
• Alendronate monosodium
• Alendronate sodium USP/EP/BP
• sodium (4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate
• ALENDRONATE
• SODIUM ALENDRONATE
• Fosamax
• (4-Amino-1-hydroxybutane-1,1-diyl)diphosphonic acid, sodium salt
• 129318-43-0
• 12126-17-5
• 29318-43-0
• C4H13NNaO7P2
• C4H13NO7P2Na
• C4H9NO7P24Na
• Alendronate